Chinese vaccine gets go-ahead for trials in Bangladesh    | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Wednesday
July 09, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
WEDNESDAY, JULY 09, 2025
Chinese vaccine gets go-ahead for trials in Bangladesh   

Covid-19 in Bangladesh

TBS Report
23 June, 2021, 05:35 pm
Last modified: 23 June, 2021, 08:57 pm

Related News

  • Hundreds of millions of life years lost to pandemic: WHO
  • Ending the austerity pandemic
  • Asian shares head for worst month since pandemic started
  • Recovery in youth employment is still lagging: ILO
  • 5 reasons to be optimistic about 2022

Chinese vaccine gets go-ahead for trials in Bangladesh   

Another Chinese vaccine candidate awaits Bangladesh Medical Research Council approval

TBS Report
23 June, 2021, 05:35 pm
Last modified: 23 June, 2021, 08:57 pm
Scientists around the world are racing to develop a vaccine. Photo: Xinhua
Scientists around the world are racing to develop a vaccine. Photo: Xinhua

Bangladesh has approved phase III trials of a Chinese Covid-19 vaccine candidate developed by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (IMBCAMS).

The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) will conduct the trial, Bangladesh Medical Research Council (BMRC) Chairman, Prof Dr Syed Modasser Ali, told The Business Standard Wednesday.

Approving the trials, the BMRC in a letter told icddr,b, "You have been approved to conduct the trial in accordance with the policy decision of the National Research Ethics Committee. Henceforth, the committee will be informed in more details."

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The BMRC asked the icddr,b to inform them as to when and where the trails will take place so that the ethics committee can monitor it.

In August 2020, the Chinese vaccine developer contacted the icddr,b, and signed a clinical trial agreement.

In December last year, the icddr,b filed an application with the medical research council on behalf of the vaccine candidate and submitted a trial protocol.    

The vaccine candidate – SARS-CoV-2 Vaccine, Inactivated (Vero Cell) – is one of seven vaccines approved for use in China.

According to www.covid-19vaccinetracker.org, the phase I trial of this vaccine began in May 2020, and its results were released in October 2020. The phase II trial for it began in June 2020, while the IMBCAMS started phase III trials late January this year in Malaysia.

This vaccine trial candidate is an inactivated (vero cell) type of vaccine like polio and influenza. Such vaccines consist of viruses grown in culture and then killed as a means to reduce virulence, that is, the ability to infect and cause harm.

The dead virus prepares the body to initiate a defence mechanism if and when an individual contracts the germ in future.

One of the benefits of vero cell type vaccines is that they can be administered to people with weakened immune systems.

There is yet another Chinese vaccine candidate awaiting BMRC approval. 
 

Bangladesh / Top News

Covid-19 pandemic / Chinese vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Clashes took place between police and protesters in Sylhet on 2 August. Photo: TBS
    Hasina authorised deadly crackdown on protesters during 2024 July uprising, BBC verifies leaked audio
  • File photo of Chattogram Port/TBS
    Cargo unloading at Ctg Port's outer anchorage suspended for three days amid rough seas
  • US Treasury Secretary Scott Bessent speaks to reporters at the US Capitol as Republican lawmakers struggle to pass US President Donald Trump’s sweeping spending and tax bill, on Capitol Hill in Washington, DC, US, June 27, 2025. Photo: REUTERS/Elizabeth Frantz/File Phot
    US could collect $300 billion in tariff revenue this year: US Treasury chief

MOST VIEWED

  • None saw it coming: What went wrong in Bangladesh’s tariff negotiation with US 
    None saw it coming: What went wrong in Bangladesh’s tariff negotiation with US 
  • File Photo: Rajib Dhar/TBS
    Bangladesh faces economic impact as US introduces 35% tariff on exports
  • Representational image. Photo: Collected
    Bangladesh reserves above $24b even after making $2b ACU payment 
  • Electric buses for capital: Tk2,500cr to be spent in 2 years
    Electric buses for capital: Tk2,500cr to be spent in 2 years
  • Representational image. Photo: TBS
    35% US tariff to be disastrous for Bangladesh's exports, say economists and exporters
  • Clashes took place between police and protesters in Sylhet on 2 August. Photo: TBS
    Hasina authorised deadly crackdown on protesters during 2024 July uprising, BBC verifies leaked audio

Related News

  • Hundreds of millions of life years lost to pandemic: WHO
  • Ending the austerity pandemic
  • Asian shares head for worst month since pandemic started
  • Recovery in youth employment is still lagging: ILO
  • 5 reasons to be optimistic about 2022

Features

Dr Mostafa Abid Khan. Sketch: TBS

Actual impact will depend on how US retailers respond: Mostafa Abid Khan

1d | Economy
Thousands gather to form Bangla Blockade in mass show of support. Photo: TBS

Rebranding rebellion: Why ‘Bangla Blockade’ struck a chord

1d | Panorama
The Mitsubishi Xpander is built with families in mind, ready to handle the daily carpool, grocery runs, weekend getaways, and everything in between. PHOTO: Akif Hamid

Now made-in-Bangladesh: 2025 Mitsubishi Xpander

2d | Wheels
Students of different institutions protest demanding the reinstatement of the 2018 circular cancelling quotas in recruitment in government jobs. Photo: Mehedi Hasan

5 July 2024: Students announce class boycott amid growing protests

4d | Panorama

More Videos from TBS

Iran receives missile shipment from China

Iran receives missile shipment from China

1h | TBS World
Will JPA be able to survive in the political arena?

Will JPA be able to survive in the political arena?

14h | TBS Stories
Trump’s steel, aluminum tariffs bleed Indian foundries

Trump’s steel, aluminum tariffs bleed Indian foundries

3h | Others
July-August uprising in memory of Chatradal leader

July-August uprising in memory of Chatradal leader

16h | TBS Stories
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net